Population health outcomes in Nigeria compared with other west African countries, 1998-2019: a systematic analysis for the Global Burden of Disease Study.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
19 03 2022
Historique:
received: 02 07 2021
revised: 12 11 2021
accepted: 23 11 2021
pubmed: 19 3 2022
medline: 25 3 2022
entrez: 18 3 2022
Statut: ppublish

Résumé

Population-level health and mortality data are crucial for evidence-informed policy but scarce in Nigeria. To fill this gap, we undertook a comprehensive assessment of the burden of disease in Nigeria and compared outcomes to other west African countries. In this systematic analysis, using data and results of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019, we analysed patterns of mortality, years of life lost (YLLs), years lived with disability (YLDs), life expectancy, healthy life expectancy (HALE), and health system coverage for Nigeria and 15 other west African countries by gender in 1998 and 2019. Estimates of all-age and age-standardised disability-adjusted life-years for 369 diseases and injuries and 87 risk factors are presented for Nigeria. Health expenditure per person and gross domestic product were extracted from the World Bank repository. Between 1998 and 2019, life expectancy and HALE increased in Nigeria by 18% to 64·3 years (95% uncertainty interval [UI] 62·2-66·6), mortality reduced for all age groups for both male and female individuals, and health expenditure per person increased from the 11th to third highest in west Africa by 2018 (US$18·6 in 2001 to $83·75 in 2018). Nonetheless, relative outcomes remained poor; Nigeria ranked sixth in west Africa for age-standardised mortality, seventh for HALE, tenth for YLLs, 12th for health system coverage, and 14th for YLDs in 2019. Malaria (5176·3 YLLs per 100 000 people, 95% UI 2464·0-9591·1) and neonatal disorders (4818·8 YLLs per 100 000, 3865·9-6064·2) were the leading causes of YLLs in Nigeria in 2019. Nigeria had the fourth-highest under-five mortality rate for male individuals (2491·8 deaths per 100 000, 95% UI 1986·1-3140·1) and female individuals (2117·7 deaths per 100 000, 1756·7-2569·1), but among the lowest mortality for men older than 55 years. There was evidence of a growing non-communicable disease burden facing older Nigerians. Health outcomes remain poor in Nigeria despite higher expenditure since 2001. Better outcomes in countries with equivalent or lower health expenditure suggest health system strengthening and targeted intervention to address unsafe water sources, poor sanitation, malnutrition, and exposure to air pollution could substantially improve population health. The Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
Population-level health and mortality data are crucial for evidence-informed policy but scarce in Nigeria. To fill this gap, we undertook a comprehensive assessment of the burden of disease in Nigeria and compared outcomes to other west African countries.
METHODS
In this systematic analysis, using data and results of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019, we analysed patterns of mortality, years of life lost (YLLs), years lived with disability (YLDs), life expectancy, healthy life expectancy (HALE), and health system coverage for Nigeria and 15 other west African countries by gender in 1998 and 2019. Estimates of all-age and age-standardised disability-adjusted life-years for 369 diseases and injuries and 87 risk factors are presented for Nigeria. Health expenditure per person and gross domestic product were extracted from the World Bank repository.
FINDINGS
Between 1998 and 2019, life expectancy and HALE increased in Nigeria by 18% to 64·3 years (95% uncertainty interval [UI] 62·2-66·6), mortality reduced for all age groups for both male and female individuals, and health expenditure per person increased from the 11th to third highest in west Africa by 2018 (US$18·6 in 2001 to $83·75 in 2018). Nonetheless, relative outcomes remained poor; Nigeria ranked sixth in west Africa for age-standardised mortality, seventh for HALE, tenth for YLLs, 12th for health system coverage, and 14th for YLDs in 2019. Malaria (5176·3 YLLs per 100 000 people, 95% UI 2464·0-9591·1) and neonatal disorders (4818·8 YLLs per 100 000, 3865·9-6064·2) were the leading causes of YLLs in Nigeria in 2019. Nigeria had the fourth-highest under-five mortality rate for male individuals (2491·8 deaths per 100 000, 95% UI 1986·1-3140·1) and female individuals (2117·7 deaths per 100 000, 1756·7-2569·1), but among the lowest mortality for men older than 55 years. There was evidence of a growing non-communicable disease burden facing older Nigerians.
INTERPRETATION
Health outcomes remain poor in Nigeria despite higher expenditure since 2001. Better outcomes in countries with equivalent or lower health expenditure suggest health system strengthening and targeted intervention to address unsafe water sources, poor sanitation, malnutrition, and exposure to air pollution could substantially improve population health.
FUNDING
The Bill & Melinda Gates Foundation.

Identifiants

pubmed: 35303469
pii: S0140-6736(21)02722-7
doi: 10.1016/S0140-6736(21)02722-7
pmc: PMC8943279
pii:
doi:

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

1117-1129

Commentaires et corrections

Type : CommentOn

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests GA is a current head of the National Agency for the Control of AIDS. CI and SA held leadership roles in the Nigerian Government during the period of writing of this paper. SA is editor in chief of BMJ Global Health. IA was a scientific and technical adviser to the Nigerian Government Presidential Task Force on COVID-19 and ZI is chair of the Nigerian national ethics committee. IA, FO, GA, SA, and IMOA are members of the Presidential Health Reform Committee. All other authors declare no competing interests.

Références

Lancet Infect Dis. 2019 Aug;19(8):872-879
pubmed: 31285143
Lancet. 2014 Sep 13;384(9947):1005-70
pubmed: 25059949
Inj Prev. 2008 Oct;14(5):284-9
pubmed: 18836043
PLoS One. 2014 Aug 14;9(8):e103754
pubmed: 25121789
Global Health. 2018 Nov 22;14(1):113
pubmed: 30466452
Bull World Health Organ. 2013 Aug 1;91(8):602-11
pubmed: 23940408
Health Econ Rev. 2020 Mar 6;10(1):5
pubmed: 32144576
Health Policy. 2010 Sep;97(1):62-70
pubmed: 20381189
Global Health. 2020 Aug 6;16(1):73
pubmed: 32762759
Health Syst Reform. 2016 Oct 1;2(4):302-318
pubmed: 31514724
Afr Health Sci. 2017 Mar;17(1):247-254
pubmed: 29026399
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Am J Trop Med Hyg. 2018 Sep;99(3_Suppl):41-47
pubmed: 30047362
Lancet. 2022 Mar 19;399(10330):1155-1200
pubmed: 35303470
Clin Infect Dis. 2019 Oct 30;69(Suppl 6):S466-S473
pubmed: 31665773
Lancet. 2019 May 11;393(10184):1958-1972
pubmed: 30954305
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
BMJ Glob Health. 2018 Apr 17;3(2):e000712
pubmed: 29707246
Soc Psychiatry Psychiatr Epidemiol. 2021 Oct;56(10):1729-1750
pubmed: 33394070
Inj Control Saf Promot. 2003 Mar-Jun;10(1-2):109-18
pubmed: 12772494
Health Policy Plan. 2019 Sep 1;34(7):529-543
pubmed: 31377775
Glob Health Action. 2020 Dec 31;13(1):1811476
pubmed: 32892738
Epidemics. 2015 Jun;11:80-4
pubmed: 25979285
Bull World Health Organ. 2010 Jun;88(6):402
pubmed: 20539847
Lancet. 2020 Oct 17;396(10258):1285-1306
pubmed: 32679112
J Public Health Afr. 2016 Aug 17;7(1):534
pubmed: 28299152
Bull World Health Organ. 2014 Jun 1;92(6):389
pubmed: 24940009
BMJ Glob Health. 2019 Aug 10;4(4):e001388
pubmed: 31478012
Lancet. 2018 Dec 23;390(10114):2803-2859
pubmed: 28917958

Auteurs

Blake Angell (B)

UCL Institute for Global Health, University College London, London, UK; The George Institute for Global Health, University of New South Wales, Sydney, Sydney, NSW, Australia.

Olutobi Sanuade (O)

UCL Institute for Global Health, University College London, London, UK; Center for Global Cardiovascular Health, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Ifedayo M O Adetifa (IMO)

Department of Infectious Diseases Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Department of Epidemiology and Demography, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Department of Paediatrics and Child Health, College of Medicine, University of Lagos, Lagos, Nigeria.

Iruka N Okeke (IN)

Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.

Aishatu Lawal Adamu (AL)

Department of Infectious Diseases Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Department of Epidemiology and Demography, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria.

Muktar H Aliyu (MH)

Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA.

Emmanuel A Ameh (EA)

Division of Paediatric Surgery, National Hospital, Abuja, Nigeria.

Fatima Kyari (F)

College of Health Sciences, University of Abuja, Abuja, Nigeria.

Muktar A Gadanya (MA)

Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria.

Diana A Mabayoje (DA)

University College London Hospitals NHS Foundation Trust, London, UK.

Adesola Yinka-Ogunleye (A)

UCL Institute for Global Health, University College London, London, UK; Nigeria Centre for Disease Control, Abuja, Nigeria.

Tolu Oni (T)

MRC Epidemiology Unit, University of Cambridge, Cambridge, UK; Research Initiative for Cities Health and Equity, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Rabiu Ibrahim Jalo (RI)

Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria.

Fatimah I Tsiga-Ahmed (FI)

Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria.

Sarah L Dalglish (SL)

UCL Institute for Global Health, University College London, London, UK.

Seye Abimbola (S)

School of Public Health, University of Sydney, Sydney, NSW, Australia.

Tim Colbourn (T)

UCL Institute for Global Health, University College London, London, UK.

Obinna Onwujekwe (O)

Health Policy Research Group, University of Nigeria Enugu Campus, Enugu, Nigeria.

Eme Theodora Owoaje (ET)

Department of Community Medicine, University of Ibadan College of Medicine, Ibadan, Nigeria.

Gambo Aliyu (G)

National Agency for the Control of AIDS, Abuja, Nigeria.

Sani H Aliyu (SH)

Infectious Disease and Microbiology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Belinda Archibong (B)

Barnard College, New York, NY, USA.

Alex Ezeh (A)

Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.

Chikwe Ihekweazu (C)

Nigeria Centre for Disease Control, Abuja, Nigeria.

Zubairu Iliyasu (Z)

Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria.

Stephen Obaro (S)

Department of Pediatric Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA.

Ebenezer Babatunde Obadare (EB)

Sociology Department, University of Kansas, Lawrence, KA, USA.

Friday Okonofua (F)

Centre of Excellence in Reproductive Health Innovation, University of Benin, Benin City, Edo State, Nigeria; University of Medical Sciences, Ondo City, Nigeria.

Muhammed Pate (M)

Health, Nutrition, and Population Global Practice and Global Financing Facility for Women, Children and Adolescents, World Bank, Washington, DC, USA; Harvard T H Chan School of Public Health, Cambridge, MA, USA.

Babatunde L Salako (BL)

Nigeria Institute for Medical Research, Lagos, Nigeria.

Fatima H Zanna (FH)

National Agency for the Control of AIDS, Abuja, Nigeria.

Scott Glenn (S)

Institute for Health Metrics and Evaluation, University of Medicine Washington, Seattle, WA, USA.

Ally Walker (A)

Institute for Health Metrics and Evaluation, University of Medicine Washington, Seattle, WA, USA.

Maha Ezalarab (M)

Institute for Health Metrics and Evaluation, University of Medicine Washington, Seattle, WA, USA.

Mohsen Naghavi (M)

Institute for Health Metrics and Evaluation, University of Medicine Washington, Seattle, WA, USA.

Ibrahim Abubakar (I)

UCL Institute for Global Health, University College London, London, UK. Electronic address: i.abubakar@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH